secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aktis Oncology, Inc. (AKTS)
CIK:        0002035832
Form:       8-K
Filed at:   2026-08-13T20:04:16+00:00
Accession:  0001193125-26-349133
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029
--------------------------------------------------------------------------

- Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.
- Cash, equivalents, marketable securities $517.3M at June 30, 2026 vs $226.8M Dec 31, 2025.
- Collaboration revenue $3.4M (Q2 2026) vs $1.6M prior-year, from Eli Lilly partnership.
- R&D expenses $25.3M, up from $18.6M; G&A $7.0M vs $3.9M year-over-year.
- Phase 1b trials: AKY-1189 (NECTINIUM-2) enrolling; AKY-2519 BActinium-2 to start H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/0001193125-26-349133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer